TargetMol

BMS 180448

Product Code:
 
TAR-T30487
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T30487-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30487-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30487-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
BMS 180448 is a prototype mitochondrial ATP-sensitive K+ (Mitok (ATP)) channel opener with cardioprotective and vasodilating properties.
CAS:
144264-47-1
Formula:
C20H18ClN5O2
Molecular Weight:
395.85
Purity:
0.98
SMILES:
CC1(C)Oc2ccc(cc2[C@H](N=C(NC#N)Nc2ccc(Cl)cc2)[C@H]1O)C#N

References

1. Lee JH, Jung IS, Lee SH, Yang MK, Hwang JH, Lee HD, Cho YS, Song MJ, Yi KY, Yoo SE, Kwon SH, Kim B, Lee CS, Shin HS. Cardioprotective effects of BMS-180448, a prototype mitoK(ATP) channel opener, and the role of salvage kinases, in the rat model of global ischemia and reperfusion heart injury. Arch Pharm Res. 2007 May;30(5):634-40. PubMed PMID: 17615684. 2. Park YS, Yoo SE, Shin HS, Jin YR, Yun YP. Pharmacological characterization of vasorelaxant effects of BMS-180448, a novel cardioselective ATP-sensitive potassium channel opener, in rat aorta. J Pharmacol Sci. 2003 Jul;92(3):218-27. PubMed PMID: 12890887. 3. Weselcouch EO, Gomoll AW. Selectivity of BMS-180448 on myocardial versus brain blood flow in dogs and ferrets. J Cardiovasc Pharmacol. 1997 Jul;30(1):61-8. PubMed PMID: 9268222. 4. Gomoll AW, Roth RA, Swillo RE, Baird AJ, Sargent CS, Behling RW, Malone HJ, Grover GJ. Effect of timing of treatment of the glyburide-reversible cardioprotective activity of BMS-180448. J Pharmacol Exp Ther. 1997 Apr;281(1):24-33. PubMed PMID: 9103476.